• Explore /
  • Poster
  • / Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial—Comparison of the efficacy of <i>KRAS</i> status.

Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial—Comparison of the efficacy of KRAS status.

Abstract Poster

Authors

Michio Nakamura

Michio Nakamura

Sapporo City General Hospital

Michio Nakamura , Satoshi Yuki , Masayoshi Dazai , Yoshimitsu Kobayashi , Takashi Kato , Hirohito Naruse , Mineo Kudo , Nobuaki Akakura , Yuh Sakata , Yoshito Komatsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00569790

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr536)

DOI

10.1200/jco.2013.31.4_suppl.536

Abstract #

536

Poster Bd #

D36

Abstract Disclosures

Similar Posters

First Author: Heinz-Josef Lenz

First Author: Satoshi Yuki

First Author: Hideaki Bando

First Author: Daniel H. Ahn